AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current ...

Richard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of ... perhaps with the usual pictures of shrinking tumours in a rat from the ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer EvolveImmune's ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

The AbbVie Foundation has donated $75 million toward the construction of UChicago Medicine's $815 million freestanding cancer care pavilion in Hyde Park. When the 575,000-square-foot building ...

Welcome to the AbbVie Third Quarter 2024 Earnings Conference ... strong growth well into the next decade. Several other key products also delivered double-digit sales growth, including Venclexta ...

The AbbVie Foundation, a nonprofit dedicated to addressing health inequities, has made a $75 million donation to the University of Chicago to support the construction of UChicago Medicine’s new cancer ...

The creation of AbbVie In 2011, Abbott announced it was to separate into two leading healthcare companies by the end of 2012. One was to be a diversified medical products company – Abbott ...